Bisphosphonates associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time†
Corresponding Author
Samantha Pozzi
Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, Italy
Department of Oncology and Hematology, Centro Oncologico Modenese, University of Modena, Modena 41100, ItalySearch for more papers by this authorRaffaella Marcheselli
Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, Italy
Search for more papers by this authorSimona Falorio
Dipartimento di Ematologia, USL di Pescara, Centro Diagnosi e Cura dei Linfomi, Ospedale Santo Spirito, Pescara, Italy
Search for more papers by this authorLuciano Masini
Ospedale “Santa Maria Nuova,” Reggio Emilia, Italy
Search for more papers by this authorCaterina Stelitano
Divisione di Ematologia, Pres. Osp. Riuniti—“Bianchi, Melacrino, Morelli,” Reggio Calabria, Italy
Search for more papers by this authorAntonietta Falcone
IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Search for more papers by this authorGiovanni Quarta
Divisione di Ematologia, Osp. A. Perrino, Brindisi, Italy
Search for more papers by this authorLuisa Ponchio
Sezione di Oncologia Medica I, Istituto Scientifico Fondazione S. Maugeri, Pavia, Italy
Search for more papers by this authorVincenzo Pitini
Dipartimento di Oncologia, Università di Messina, Messina, Italy
Search for more papers by this authorStefano Luminari
Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, Italy
Search for more papers by this authorLuca Baldini
UO Ematologia 1/CTMO, Ospedale Maggiore Policlinico MaRe, IRCCS, Università degli Studi, Milan, Italy
Search for more papers by this authorCorresponding Author
Samantha Pozzi
Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, Italy
Department of Oncology and Hematology, Centro Oncologico Modenese, University of Modena, Modena 41100, ItalySearch for more papers by this authorRaffaella Marcheselli
Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, Italy
Search for more papers by this authorSimona Falorio
Dipartimento di Ematologia, USL di Pescara, Centro Diagnosi e Cura dei Linfomi, Ospedale Santo Spirito, Pescara, Italy
Search for more papers by this authorLuciano Masini
Ospedale “Santa Maria Nuova,” Reggio Emilia, Italy
Search for more papers by this authorCaterina Stelitano
Divisione di Ematologia, Pres. Osp. Riuniti—“Bianchi, Melacrino, Morelli,” Reggio Calabria, Italy
Search for more papers by this authorAntonietta Falcone
IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Search for more papers by this authorGiovanni Quarta
Divisione di Ematologia, Osp. A. Perrino, Brindisi, Italy
Search for more papers by this authorLuisa Ponchio
Sezione di Oncologia Medica I, Istituto Scientifico Fondazione S. Maugeri, Pavia, Italy
Search for more papers by this authorVincenzo Pitini
Dipartimento di Oncologia, Università di Messina, Messina, Italy
Search for more papers by this authorStefano Luminari
Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, Italy
Search for more papers by this authorLuca Baldini
UO Ematologia 1/CTMO, Ospedale Maggiore Policlinico MaRe, IRCCS, Università degli Studi, Milan, Italy
Search for more papers by this authorConflict of Interest: Nothing to report.
References
- 1 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–1117.
- 2 Ruggiero SL,Mehrotra B,Rosenberg TJ,Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62(5): 527–534.
- 3 Pozzi S,Marcheselli R,Sacchi S, et al. Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007; 48: 56–64.
- 4 Khosla S,Burr D,Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American society for bone and mineral research. J Bone Miner Res 2007; 22: 1479–1491.
- 5 Badros A,Evangelos T,Goloubeva O, et al. Long-term follow-up of multiple myeloma (MM) patients (pts) with osteonecrosis of the jaw (ONJ). American Society of Hematology. Blood 2007; 110: 3519.
- 6 Mehrotra B,Fantasia J,Ruggiero S. Outcomes of bisphosphonate-related osteonecrosis of the jaw-importance of staging and management guidelines: A large single institution update. American Society of Clinical Oncology. J Clin Oncol 2008; 20526.
- 7 Wang EP,Kaban LB,Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65: 1328–1331.
- 8 Hoff AO,Toth BB,Altundag K, et al. The frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826–836.
- 9 Dimopoulos MA,Kastritis E,Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117–120.
Citing Literature
